Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | NR3C2 | P08235 | 7/20 | 0.53 |
| ▸ | PDE5A | O76074 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | GLA | P06280 | 4/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ATM | Q13315 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.51 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4594248 | 0.96 | MEN1 (0.58) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL4592755 | 0.84 | MEN1 (0.67) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL4594252 | 0.80 | GAA (0.39) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL28573013 | 0.77 | EGFR (0.61) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL28582464 | 0.77 | MEN1 (0.55) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL9203820 | 0.76 | PRKCZ (0.48) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL28545366 | 0.75 | EGFR (0.70) | GAAMEN1KMT2ANR3C2PDE5A | |
| SCHEMBL4254323 | 0.75 | MEN1 (0.87) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL31429937 | 0.75 | MEN1 (0.82) | GAAMEN1KMT2AHSP90AA1NR3C2 | |
| SCHEMBL19471296 | 0.71 | GAA (0.73) | GAAMEN1KMT2AHSP90AA1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-14 | — | — | US | claimed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | claimed |
| EP-1023066-A4 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORP (US) | 2001-05-23 | — | — | EP | claimed |
| EP-1023066-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-08-02 | — | — | EP | claimed |
| WO-1998056377-A1 | NOVEL PYRAZOLE AND PYRAZOLINE SUBSTITUTED COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-12-17 | — | — | WO | claimed |
| EP-1539121-A4 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | PROTTER ANDREW A | 2008-05-08 | — | — | US | disclosed |
| EP-1583535-A4 | METHODS FOR TREATING DIABETES | SCIOS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | PROTTER ANDREW A | 2008-02-14 | — | — | US | disclosed |
| US-7268139-B2 | Methods of promoting osteogenesis | SCIOS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7244441-B2 | Stents and intra-luminal prostheses containing map kinase inhibitors | SCIOS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| EP-1676574-A2 | Methods for promoting survival of transplanted tissues and cells | Johnson & Johnson Vision Care, Inc. (US) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005032551-A1 | TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20040171659-A1 | Methods for treating diabetes | SCIOS, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040162289-A1 | Methods of promoting osteogenesis | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2004-08-19 | — | — | US | disclosed |
| US-6774127-B2 | TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | SCIOS, INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004053107-A2 | METHODS FOR TREATING DIABETES | SCIOS INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| WO-2004019873-A2 | METHODS OF PROMOTING OSTEOGENESIS | SCIOS INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108658-A1 | METHODS OF PROMOTING OSTEOGENESIS | MAPK1, BMP2, MAPK3 | GAA 1425/4885MEN1 1366/4885KMT2A 2643/4885 |
| US-20040162289-A1 | Methods of promoting osteogenesis | MAPK1, BMP2, MAPK3 | GAA 1425/4885MEN1 1366/4885KMT2A 2643/4885 |
| US-20030153569-A1 | Novel pyrazole and pyrazoline substituted compounds | PDXK, COQ8A, PDK3 | GAA 3284/4885MEN1 3265/4885KMT2A 3711/4885 |
| US-20040122008-A1 | Treatment of pain by inhibition of p38 MAP kinase | OPRK1, OPRL1, MAPK3 | GAA 4058/4885MEN1 4518/4885KMT2A 4237/4885 |
| US-20080039461-A1 | Treatment of pain by inhibition of p38 map kinase | OPRK1, OPRL1, MAPK3 | GAA 4058/4885MEN1 4518/4885KMT2A 4237/4885 |
| US-20040171659-A1 | Methods for treating diabetes | SLC5A2, MAPK4, MAPK3 | GAA 1011/4885MEN1 4158/4885KMT2A 3019/4885 |
| US-20020156104-A1 | CSBP/p38/RK kinase inhibitors | MAPKAPK2, MAPKAPK3, MAPKAPK5 | GAA 4787/4885MEN1 4619/4885KMT2A 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.